Baseline characteristics | Treatment group at start | ||
---|---|---|---|
Clinical and Cognitive Scales | Placebo (N = 39) | Atabecestat | |
10 mg (N = 37) | 50 mg (N = 38) | ||
CDR-SB†,N | 39 | 37 | 38 |
All mean (SD) | 1.5 (1.25) | 1.6 (1.24) | 1.6 (1.09) |
Preclinical AD,N | 7 | 8 | 9 |
Mean (SD) | 0.1 (0.19) | 0.4 (0.73) | 0.8 (0.97) |
MCI due to AD,N | 32 | 29 | 29 |
Mean (SD) | 1.8 (1.16) | 1.9 (1.16) | 1.8 (1.04) |
CVLT-II, long-delay recall‖,N | 36 | 36 | 37 |
All mean (SD) | 11.7 (9.4) | 10.3 (9.04) | 12.4 (8.48) |
Preclinical AD,N | 7 | 8 | 9 |
Mean (SD) | 19.7 (7.67) | 15.8 (12.29) | 20.7 (8.14) |
MCI due to AD,N | 29 | 28 | 28 |
Mean (SD) | 9.7 (8.46) | 8.8 (7.45) | 9.8 (6.80) |
MMSE subscale scores‡,N | 39 | 37 | 38 |
All mean (SD) | 26.3 (2.90) | 24.9 (4.14) | 26.2 (2.47) |
Preclinical AD,N | 7 | 8 | 9 |
Mean (SD) | 29.0 (1.15) | 27.8 (2.55) | 27.8 (2.64) |
MCI due to AD,N | 32 | 29 | 29 |
Mean (SD) | 25.8 (2.84) | 24.1 (4.18) | 25.7 (2.24) |
RBANS—total scale score¶,N | 39 | 37 | 38 |
All, mean (SD) | 80.2 (17.10) | 72.4 (21.99) | 80.1 (17.44) |
Preclinical AD,N | 7 | 8 | 9 |
Mean (SD) | 99.7 (14.68) | 91.4 (23.89) | 92.9 (17.49) |
MCI due to AD,N | 32 | 29 | 29 |
Mean (SD) | 75.9 (14.55) | 67.2 (18.66) | 76.2 (15.68) |